Dermatitis, Atopic

Amgen, Kyowa Kirin Bolster Safety Profile for Atopic Dermatitis Drug Rocatinlimab

1 week ago talkbio0Tagged amgen, ASCEND trial, Dermatitis, Atopic, Eczema, Kyowa Kirin, Long-term, OX40 receptor, Programs - Publication Format, Rocatinlimab, Rocket, Safety

Amgen; Kyowa Kirin; rocatinlimab; atopic dermatitis; OX40 receptor; ASCEND trial; ROCKET program; long-term safety; eczema

Enveda Raises $150M Series D, Advances Nature-Inspired Drug Programs

2 weeks ago talkbio0Tagged Biosciences, Dermatitis, Atopic, Enveda, Immune System Diseases, Investments, Mikael, nature-inspired drug discovery, Series D

Enveda Biosciences; Series D funding; $150 million; nature-inspired drug discovery; atopic dermatitis; immune diseases; Mikael Dolsten; biotech investment

Sanofi Phase 3 Eczema Win Falls Short of Analyst Expectations

2 weeks ago talkbio0Tagged Amlitelimab, Dermatitis, Atopic, Dupixent, EASI-75, Eczema, Expectations, Market, Reaction, sanofi

Sanofi; amlitelimab; phase 3 trial; eczema; atopic dermatitis; analyst expectations; Dupixent; EASI-75; market reaction

Akeso Scores Two Wins in Phase 3 Trials, Tees Up Regulatory Submissions in China

3 weeks ago talkbio0Tagged Akeso, Ankylosing spondylitis, Autoimmune Diseases, China, Clinical Trials, Dermatitis, Atopic, Gumokimab, Manfidokimab, regulatory submission

Akeso; Phase 3 trials; gumokimab; manfidokimab; ankylosing spondylitis; atopic dermatitis; regulatory submission; China; autoimmune diseases; clinical trial results

Nektar Declares Phase IIb Eczema Win for Rezpeg, but Analysts Remain Skeptical

3 months ago talkbio0Tagged analysts, Clinical Trials, Dermatitis, Atopic, Dupixent, EASI, Eczema, Lilly partnership, Nektar Therapeutics, Phase II B Trial, Rezpeg, Rezpegaldesleukin, Score, Skepticism

Nektar Therapeutics; Rezpegaldesleukin; Rezpeg; Phase IIb trial; eczema; atopic dermatitis; clinical trial; EASI score; Dupixent; analyst skepticism; Lilly partnership

Sanofi Increases Investment in Nurix-Partnership for STAT6 Program

4 months ago talkbio0Tagged Asthma, biotech collaboration, DEL-AI, Dermatitis, Atopic, Drug Discovery, Licensing Deal, Nurix, NX-3911, protein degrader, sanofi, STAT6

Sanofi; Nurix Therapeutics; STAT6; NX-3911; protein degrader; atopic dermatitis; asthma; drug discovery; licensing deal; DEL-AI platform; biotech collaboration

Galderma’s Nemluvio Secures Dual EU Approvals for Atopic Dermatitis and Prurigo Nodularis

7 months ago talkbio0Tagged Commission approval, Dermatitis, Atopic, European (ethnic group), Galderma, IL-31 receptor alpha, Monoclonal Antibodies, Nemluvio, nemolizumab, nodularis, Prurigo

Nemluvio, nemolizumab, Galderma, European Commission approval, atopic dermatitis, prurigo nodularis, IL-31 receptor alpha, monoclonal antibody

Allakos Announces Discontinuation of AK006 Program and 75% Layoffs Following Clinical Trial Failures

8 months ago talkbio0Tagged AK006, Allakos, chronic, Clinical Trials, Dermatitis, Atopic, Failure (biologic function)

Allakos, AK006, clinical trial failure, layoffs, biotech, chronic spontaneous urticaria, atopic dermatitis

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Advance Development of Atopic Dermatitis Treatment

9 months ago talkbio0Tagged Biological Factors, Clinical stage finding, Dermatitis, Atopic, Ikena Oncology, IMG-007, Implantation procedure, Inmagene Biopharmaceuticals, Merger, Monoclonal Antibodies, Private Room, TNFRSF4 gene

Ikena Oncology, Inmagene Biopharmaceuticals, Merger, Atopic Dermatitis, IMG-007, Monoclonal Antibody, OX40, Biopharmaceuticals, Clinical Stage, Private Placement

FDA Approves Expanded Use of VTAMA and Nemluvio for Atopic Dermatitis Treatment

9 months ago talkbio0Tagged Approved, Dermatitis, Atopic, Dermatologic disorders, Dermatology field, Galderma, Nemluvio, Organon, United States Food and Drug Administration, Vtama

FDA approval, atopic dermatitis, VTAMA, Nemluvio, Galderma, Organon, dermatology, skin conditions